Literature DB >> 20479048

Pan-Canadian review of cancer drugs will not be binding on provinces.

Lauren Vogel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20479048      PMCID： PMC2882446          DOI： 10.1503/cmaj.109-3262

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Variation and consternation: access to unfunded cancer drugs in Canada.

Authors:  Scott R Berry; William K Evans; Elizabeth L Strevel; Chaim M Bell
Journal:  J Oncol Pract       Date:  2012-01       Impact factor: 3.840

2.  Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces.

Authors:  Dixon T S Woon; Thenappan Chandrasekar; Lorne Aaron; Naveen S Basappa; Kim N Chi; Henry J Conter; Geoffrey Gotto; Sebastien J Hotte; Shawn Malone; Fred Saad; Bobby Shayegan; Laura Park-Wyllie; Robert J Hamilton
Journal:  Can Urol Assoc J       Date:  2018-07-16       Impact factor: 1.862

3.  Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada.

Authors:  J Amdahl; J Diaz; J Park; H R Nakhaipour; T E Delea
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.